Jean-Marc Bellemin

Former Chief Financial OfficeratIovance Biotherapeutics· In proxies 2021–2025

Pay in FY2025-80% from the year before · Iovance Biotherapeutics stock -63.1% the same year

Jean-Marc Bellemin was paid $663.1K in FY2025 (Dec), down 80%. Iovance Biotherapeutics stock fell 63.1% that year.

Pay$100 in the stock at the end of FY20 → $6

Pay is from the Summary Compensation Table of each Iovance Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

IOVA
Iovance BiotherapeuticsPublic company · 5 yr
- Former Chief Financial Officer2021 – Present · 5 yrStock in role -70%

Roles come from the proxy statements of each company.

Activity

Pay
Iovance Biotherapeutics Former CFO pay fell 80% to $663.1K. The stock fell 63% in FY2025 (Dec).
DEF 14AApr 28, 2026
Pay
Iovance Biotherapeutics Former CFO pay rose 90% to $3.2M. The stock fell 9% in FY2024 (Dec).
DEF 14AApr 28, 2025
Pay
Iovance Biotherapeutics Former CFO pay fell 22% to $1.7M. The stock rose 27% in FY2023 (Dec).
DEF 14AApr 29, 2024
Pay
Iovance Biotherapeutics Former CFO pay rose 44% to $2.2M. The stock fell 67% in FY2022 (Dec).
DEF 14AApr 29, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?